RxDoctor Payments Data

Mike Cusnir, MD

Hematology & Oncology · Miami Beach, FLNPI 1962490631

Payments from drug & device makers

$1,988,199in general payments, 2019–2025

Across 2,928 payments — averaging $679.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$767K
  • Mirati Therapeutics, Inc.$175K
  • Exelixis Inc.$110K
  • Incyte Corporation$96K
  • Otsuka Pharmaceutical Co., Ltd.$96K
  • Taiho Oncology, Inc.$94K
  • plus $647K from 54 others

What the payments were for

  • Consulting fees$41,02123%
  • Speaking & faculty fees$88,08849%
  • Travel & lodging$6,1923%
  • Food & beverage$44,44625%
  • Education$1,6091%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer212$766,641
Mirati Therapeutics, Inc.80$175,308
Exelixis Inc.49$110,492
Incyte Corporation271$95,661
Otsuka Pharmaceutical Co., Ltd.17$95,612
Taiho Oncology, Inc.36$94,428
Sirtex Medical Inc92$83,179
Rigel Pharmaceuticals, Inc.31$72,881
Genmab U.S., Inc.25$70,418
Janssen Research & Development, LLC8$64,426
Iovance Biotherapeutics, Inc.11$55,939
Ipsen Bioscience Inc.9$54,037
Seagen Inc.45$31,120
EMD Serono, Inc.86$29,695
Novocure Inc.16$25,433
AVEO Pharmaceuticals, Inc.8$19,549
Gilead(2 entities)38$14,592
Eisai Inc.62$14,565
Genentech, Inc.5$12,838
Ipsen Biopharmaceuticals, Inc31$12,104
Servier Bioinnovation2$10,273
Institut DE Recherches Internationales Servier6$9,182
AstraZeneca(2 entities)142$7,604
Jazz Pharmaceuticals Inc.10$5,768
Bristol Myers Squibb149$5,699
Veru Inc.4$5,595
Novartis121$4,597
Pfizer Chile S.A.2$4,311
Lilly USA, LLC22$3,972
Merck101$3,436
Johnson & Johnson(2 entities)251$3,255
Sanofi-aventis U.S. LLC3$2,075
Beigene USA, Inc.32$2,046
Astellas Pharma US Inc86$1,774
Genentech USA, Inc.94$1,623
Bayer78$1,501
Array Biopharma Inc42$1,338
Sanofi53$1,310
E.r. Squibb & Sons, L.L.C.60$1,115
Daiichi Sankyo Inc.49$1,032
AbbVie33$747
Amgen48$723
Pharmacyclics LLC, An Abbvie Company34$698
Epizyme, Inc.17$619
GSK27$593
Sumitomo Pharma America, Inc.20$459
Beigene, Ltd.1$450
Takeda Pharmaceuticals U.S.A., Inc.18$436
Regeneron Healthcare Solutions, Inc.16$435
Tempus AI, Inc9$389
Boehringer Ingelheim14$343
Springworks Therapeutics, Inc.11$333
Deciphera Pharmaceuticals Inc.15$317
Dendreon Pharmaceuticals LLC11$314
Adaptive Biotechnologies Corporation14$305
Immunomedics, Inc.1$281
Clovis Oncology, Inc.11$264
Beone Medicines USA, Inc.8$262
Foundation Medicine, Inc.11$238
Karyopharm Therapeutics Inc.12$234

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,988,199 in reported general payments places this provider in the 90th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida

Medicare billing

Part B allowed, 2024
$119,097
Medicare patients
464
Services billed
1,550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide72$1,226,691
XtandiEnzalutamide83$1,119,802
ErleadaApalutamide54$776,664
LenvimaLenvatinib Mesylate26$570,630
Lenalidomide40$540,847
LynparzaOlaparib35$490,222
TagrissoOsimertinib Mesylate24$386,609
TalzennaTalazoparib Tosylate22$337,695
IbrancePalbociclib19$335,418
JakafiRuxolitinib Phosphate13$260,359
KisqaliRibociclib Succinate25$237,070
CalquenceAcalabrutinib Maleate12$196,393
VerzenioAbemaciclib11$170,319
CreonLipase/Protease/Amylase41$102,952
Abiraterone Acetate100$101,028

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$5,699$1,226,69172 claims
Astellas Pharma US IncXtandi$1,774$1,119,80283 claims
AstraZenecaLynparza, Tagrisso, Calquence$7,604$1,073,22471 claims
Johnson & JohnsonErleada$3,255$776,66454 claims
PfizerTalzenna, Ibrance, Eliquis$766,641$721,10296 claims
Eisai Inc.Lenvima$14,565$570,63026 claims
Incyte CorporationJakafi$95,661$260,35913 claims
NovartisKisqali$4,597$237,07025 claims
Lilly USA, LLCVerzenio$3,972$170,31911 claims
AbbVieCreon$747$102,95241 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 694 hematology & oncology providers in Florida.

Other hematology & oncology in Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →